"I have consistently expressed my concern to the committee that I do not think requiring a reduction in price for a streamlined cost pathway is an appropriate way forward," said Medicines Australia chief executive Liz de Somer. …
'If it is necessary for me to formally dissent in the final report, I will do so'
February 1, 2024 Latest NewsBioPharmaBioPharmaDispatch ExecutiveNews of the Day
Latest Video
New Stories
-
Blood test for eight cancers arrives in Australia, but misses almost half of them
September 23, 2026 - -
Prescient raises $6 million to carry cancer drug PTX-100 past a key dosing decision
September 23, 2026 - - Australian Biotech -
Seven Australian startups share $15.6 million to take on dementia
September 23, 2026 - - Australian Biotech -
Dimerix draws $17 million from loan facility to fund kidney drug trials to completion
September 23, 2026 - - Australian Biotech -
Actinogen's Alzheimer's pill nears its moment of truth as final trial patient is seen
September 23, 2026 - - Australian Biotech -
Patrys doses first volunteers in trial of intravenous quetiapine for delirium
September 23, 2026 - - Australian Biotech -
Lilly goes direct with a patient platform for its non-PBS medicines
September 23, 2026 - - Latest News